Prati Daniele, Caprioli Flavio, Stea Luisa, Berzuini Alessandra, Pizzotti Denise, Petrillo Errica, Coluccio Elena, Erba Elisa, Lamorte Giuseppe, Ferrari Francesca, Cariani Lisa, Amoroso Chiara, Preti Anna C, Bandera Alessandra, Callegaro Annapaola, Castaldi Silvana, Cardillo Massimo, Vecchi Maurizio, Valenti Luca, De Angelis Vincenzo
Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
National Blood Centre, Italian National Institute of Health, Rome, Italy.
Blood Transfus. 2025 May-Jun;23(3):275-282. doi: 10.2450/BloodTransfus.929. Epub 2025 Mar 12.
Fecal Microbiota Transplantation (FMT) is an innovative therapy with growing applications, particularly for recurrent Clostridioides difficile infections (rCDI). However, the broader use of FMT is challenged by the complexities of donor recruitment, the necessity of stringent screening protocols, and the need for maintaining high-quality stool biobanks. This paper explores the integration of FMT programs within transfusion medicine departments, taking advantage of their expertise in donor management and biological material processing. Despite the complexities of donor screening, including a low eligibility rate, the collaboration between transfusion services and other hospital departments demonstrates a viable model for expanding FMT access. Additionally, the recent EU regulations on substances of human origin (SoHO) offer a framework for standardizing and scaling stool banking, enhancing the safety and efficacy of FMT procedures.
粪便微生物群移植（FMT）是一种应用日益广泛的创新疗法，尤其适用于复发性艰难梭菌感染（rCDI）。然而，FMT的更广泛应用面临着供体招募的复杂性、严格筛查方案的必要性以及维持高质量粪便生物样本库的需求等挑战。本文探讨了FMT项目在输血医学部门的整合，利用其在供体管理和生物材料处理方面的专业知识。尽管供体筛查存在复杂性，包括合格率较低，但输血服务部门与其他医院科室之间的合作展示了一种扩大FMT可及性的可行模式。此外，欧盟最近关于人类源物质（SoHO）的法规为规范和扩大粪便库提供了框架，提高了FMT程序的安全性和有效性。
